<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>APPROVED</status><version>v2</version><patient-age>66</patient-age><report-id>US-CELGENEUS-163-21880-13013011</report-id><gender>male</gender><reactions><reaction>DISEASE PROGRESSION (MULTIPLE MYELOMA)</reaction><reaction>FLU</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>REVLIMID</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>FLUVIRIN</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>SYNTHROID</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>LISINOPRIL</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>MS CONTIN</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>WARFARIN</drug-name><manufacturer/><ingredients/></drug></drugs><indications><indication>10028228</indication><indication>10057097</indication></indications><outcomes><outcome>Life Threatening</outcome><outcome>Required Inpatient Hospitalization</outcome></outcomes><country>United States</country><geo/></meta><original><ichicsr lang="en" xmlns="">
  <ichicsrmessageheader lang="en">
    <messagetype>ichicsr</messagetype>
    <messageformatversion>2.1</messageformatversion>
    <messageformatrelease>2.0</messageformatrelease>
    <messagenumb>CEL000000000001289018</messagenumb>
    <messagesenderidentifier>CELGENE</messagesenderidentifier>
    <messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
    <messagedateformat>204</messagedateformat>
    <messagedate>20130125101403</messagedate>
  </ichicsrmessageheader>
  <safetyreport lang="en">
    <safetyreportversion lang="en">0</safetyreportversion>
    <safetyreportid lang="en">US-CELGENEUS-163-21880-13013011</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>2013-01-25</transmissiondate>
    <reporttype>1</reporttype>
    <serious code="1">Yes</serious>
    <seriousnesslifethreatening>1</seriousnesslifethreatening>
    <seriousnesshospitalization>1</seriousnesshospitalization>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>2013-01-18</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>2013-01-18</receiptdate>
    <additionaldocument>2</additionaldocument>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb lang="en">US-CELGENEUS-163-21880-13013011</companynumb>
    <medicallyconfirm>1</medicallyconfirm>
    <linkedreport>
      <linkreportnumb>US-CELGENE-163-21880-08091561</linkreportnumb>
    </linkedreport>
    <linkedreport>
      <linkreportnumb>US-CELGENE-163-21880-09102348</linkreportnumb>
    </linkedreport>
    <primarysource>
      <reportergivename>Tom</reportergivename>
      <reporterfamilyname>Matthews</reporterfamilyname>
      <reporterstreet>Walgreens Specialty Pharmacy, 7164 Technology Drive, Suite 100</reporterstreet>
      <reportercity>Frisco</reportercity>
      <reporterstate>TX</reporterstate>
      <reporterpostcode>75034</reporterpostcode>
      <reportercountry>US</reportercountry>
      <qualification code="2">Pharmacist</qualification>
    </primarysource>
    <sender>
      <sendertype>1</sendertype>
      <senderorganization>CELGENEUS</senderorganization>
      <senderdepartment>Global Drug Safety</senderdepartment>
      <sendertitle>Manager</sendertitle>
      <sendergivename>Vivian</sendergivename>
      <senderfamilyname>Fonseca</senderfamilyname>
      <senderstreetaddress>300 Connell Drive, Suite 6000</senderstreetaddress>
      <sendercity>Berkeley Heights</sendercity>
      <senderstate>NJ</senderstate>
      <senderpostcode>07922</senderpostcode>
      <sendercountrycode>US</sendercountrycode>
      <sendertel>9082190331</sendertel>
      <senderfax>9086739115</senderfax>
      <senderemailaddress>vfonseca@celgene.com</senderemailaddress>
    </sender>
    <receiver>
      <receivertype>2</receivertype>
      <receiverorganization>FDAPM</receiverorganization>
      <receivergivename>Roger</receivergivename>
      <receivermiddlename>A</receivermiddlename>
      <receiverfamilyname>Goetsch</receiverfamilyname>
      <receivercountrycode>US</receivercountrycode>
    </receiver>
    <patient lang="en">
      <patientinitial>J-T</patientinitial>
      <patientbirthdateformat>102</patientbirthdateformat>
      <patientbirthdate>19460427</patientbirthdate>
      <patientsex code="1">Male</patientsex>
      <patientmedicalhistorytext lang="en">None Provided</patientmedicalhistorytext>
      <reaction>
        <primarysourcereaction lang="en">DISEASE PROGRESSION (MULTIPLE MYELOMA)</primarysourcereaction>
        <reactionmeddraversionllt>15.1</reactionmeddraversionllt>
        <reactionmeddrallt>10067095</reactionmeddrallt>
        <reactionmeddraversionpt>15.1</reactionmeddraversionpt>
        <reactionmeddrapt>10028228</reactionmeddrapt>
        <termhighlighted>3</termhighlighted>
        <reactionstartdateformat>102</reactionstartdateformat>
        <reactionstartdate>20130114</reactionstartdate>
        <reactionfirsttime>9</reactionfirsttime>
        <reactionfirsttimeunit>802</reactionfirsttimeunit>
        <reactionoutcome code="3">not recovered/not resolved</reactionoutcome>
      </reaction>
      <reaction>
        <primarysourcereaction lang="en">FLU</primarysourcereaction>
        <reactionmeddraversionllt>15.1</reactionmeddraversionllt>
        <reactionmeddrallt>10016790</reactionmeddrallt>
        <reactionmeddraversionpt>15.1</reactionmeddraversionpt>
        <reactionmeddrapt>10022000</reactionmeddrapt>
        <termhighlighted>1</termhighlighted>
        <reactionoutcome code="6">unknown</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization code="1">suspsect</drugcharacterization>
        <medicinalproduct>REVLIMID</medicinalproduct>
        <obtaindrugcountry>US</obtaindrugcountry>
        <drugauthorizationnumb>21-880</drugauthorizationnumb>
        <drugauthorizationcountry>US</drugauthorizationcountry>
        <drugauthorizationholder>Celgene Corporation</drugauthorizationholder>
        <drugstructuredosagenumb>25</drugstructuredosagenumb>
        <drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
        <drugseparatedosagenumb>21</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>21</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
        <drugdosagetext lang="en">25 Milligram</drugdosagetext>
        <drugdosageform normalized="capsule">Capsules</drugdosageform>
        <drugadministrationroute code="048">Oral</drugadministrationroute>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10028228</drugindication>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>2012-04-01</drugstartdate>
        <drugstartperiod>9</drugstartperiod>
        <drugstartperiodunit>802</drugstartperiodunit>
        <drugenddateformat>102</drugenddateformat>
        <drugenddate>2013-01-14</drugenddate>
        <drugtreatmentduration>9</drugtreatmentduration>
        <drugtreatmentdurationunit code="802">Month</drugtreatmentdurationunit>
        <actiondrug code="1">Drug Withdrawn</actiondrug>
        <drugrecurreadministration code="3">Unknown</drugrecurreadministration>
        <activesubstance>
          <activesubstancename>LENALIDOMIDE</activesubstancename>
        </activesubstance>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10067095</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Suspected</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10067095</drugreactionasses>
          <drugassessmentsource lang="en">Company</drugassessmentsource>
          <drugresult lang="en">Not Related</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10016790</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Not Provided</drugresult>
        </drugreactionrelatedness>
      </drug>
      <drug>
        <drugcharacterization code="2">concomitant</drugcharacterization>
        <medicinalproduct>FLUVIRIN</medicinalproduct>
        <obtaindrugcountry>US</obtaindrugcountry>
        <drugdosageform normalized="unknown">Unknown</drugdosageform>
        <drugadministrationroute code="065">Unknown</drugadministrationroute>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10057097</drugindication>
        <activesubstance>
          <activesubstancename>INFLUENZA VIRUS VACCINE POLYVALENT</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization code="2">concomitant</drugcharacterization>
        <medicinalproduct>SYNTHROID</medicinalproduct>
        <obtaindrugcountry>US</obtaindrugcountry>
        <drugstructuredosagenumb>0.15</drugstructuredosagenumb>
        <drugstructuredosageunit code="004">micrograms</drugstructuredosageunit>
        <drugdosageform normalized="unknown">Unknown</drugdosageform>
        <drugadministrationroute code="065">Unknown</drugadministrationroute>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10057097</drugindication>
        <activesubstance>
          <activesubstancename>LEVOTHYROXINE SODIUM</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization code="2">concomitant</drugcharacterization>
        <medicinalproduct>LISINOPRIL</medicinalproduct>
        <obtaindrugcountry>US</obtaindrugcountry>
        <drugstructuredosagenumb>10</drugstructuredosagenumb>
        <drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
        <drugdosageform normalized="unknown">Unknown</drugdosageform>
        <drugadministrationroute code="065">Unknown</drugadministrationroute>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10057097</drugindication>
        <activesubstance>
          <activesubstancename>LISINOPRIL</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization code="2">concomitant</drugcharacterization>
        <medicinalproduct>MS CONTIN</medicinalproduct>
        <obtaindrugcountry>US</obtaindrugcountry>
        <drugstructuredosagenumb>15</drugstructuredosagenumb>
        <drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
        <drugdosageform normalized="unknown">Unknown</drugdosageform>
        <drugadministrationroute code="065">Unknown</drugadministrationroute>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10057097</drugindication>
        <activesubstance>
          <activesubstancename>MORPHINE SULFATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization code="2">concomitant</drugcharacterization>
        <medicinalproduct>WARFARIN</medicinalproduct>
        <obtaindrugcountry>US</obtaindrugcountry>
        <drugstructuredosagenumb>3</drugstructuredosagenumb>
        <drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
        <drugdosageform normalized="unknown">Unknown</drugdosageform>
        <drugadministrationroute code="065">Unknown</drugadministrationroute>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10057097</drugindication>
        <activesubstance>
          <activesubstancename>WARFARIN</activesubstancename>
        </activesubstance>
      </drug>
      <summary lang="en">
        <narrativeincludeclinical><Semaphore x="2910051" class="MedDRA LLT" value="Disease progression" score="1.00" ID="10061818">DISEASE <Semaphore x="3115684" class="MedDRA LLT" value="Multiple myeloma" score="1.00" ID="10028228">PROGRESSION </Semaphore></Semaphore>
    <Semaphore x="3115684" class="MedDRA LLT" value="Multiple myeloma" score="1.00" ID="10028228">(<Semaphore x="2405273" class="Disease or Finding" value="Plasma Cell Myeloma" score="1.00" ID="C3242">MULTIPLE MYELOMA</Semaphore></Semaphore>), <Semaphore x="2056128" class="Disease or Finding" value="Influenza" score="1.00" ID="C53482">FLU</Semaphore>(USA) <Semaphore x="1938518" class="Disease or Finding" value="First-Degree Burn" score="1.00" ID="C76130">Initial </Semaphore>information was received on 18/Jan/2013 with subsequent information received on 21Jan2013 from a <Semaphore x="2009300" class="Occupation" value="Health Care Professional" score="1.00" ID="C53287">health care professional </Semaphore>regarding a <Semaphore x="1387834" class="Patient Age" value="66" score="1.00" ID=""><Semaphore x="5960701642276865" class="Patient Age" value="66" score="1.00" ID="">66 </Semaphore>year old </Semaphore>male who received <Semaphore x="1131427" class="Medicine" value="Revlimid" score="0.74" ID="256603">Revlimid </Semaphore><Semaphore x="4859317408759809" class="Medicine - Revlimid - Dose" value="25 mg" score="0.49" ID="">25 mg </Semaphore><Semaphore x="4859377538301953" class="Medicine - Revlimid - Frequency" value="capsules" score="0.49" ID="">capsules </Semaphore><Semaphore x="2336704" class="AnatomicStructure" value="Oral Cavity" score="1.00" ID="C12421">orally </Semaphore>daily for 21 days from /Apr/2012 to 14Jan2013 for the <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>of <Semaphore x="3115684" class="MedDRA LLT" value="Multiple myeloma" score="1.00" ID="10028228">multiple myeloma</Semaphore>. Lot number was A0177A and expiration date was 31/JAN/2015. Relevant medical history was not reported. Concomitant medications included Fluvirin, <Semaphore x="1243220" class="Medicine" value="Synthroid" score="0.49" ID="249232">Synthroid</Semaphore>, <Semaphore x="793322" class="Medicine" value="Lisinopril" score="0.49" ID="243048">Lisinopril</Semaphore>, <Semaphore x="887167" class="Medicine" value="MS Contin" score="0.49" ID="241535"><Semaphore x="3115917" class="MedDRA LLT" value="Multiple sclerosis" score="1.00" ID="10028245">MS </Semaphore>Contin</Semaphore>, and <Semaphore x="1361170" class="Medicine" value="Warfarin" score="0.49" ID="196877">Warfarin</Semaphore>.The patient experienced <Semaphore x="2910051" class="MedDRA LLT" value="Disease progression" score="1.00" ID="10061818">disease <Semaphore x="3115684" class="MedDRA LLT" value="Multiple myeloma" score="1.00" ID="10028228">progression </Semaphore></Semaphore>
    <Semaphore x="3115684" class="MedDRA LLT" value="Multiple myeloma" score="1.00" ID="10028228">(multiple myeloma</Semaphore>) on 14Jan2013 and was hospitalized. The patient also experienced the <Semaphore x="2056128" class="Disease or Finding" value="Influenza" score="1.00" ID="C53482">flu </Semaphore>(onset date not reported). The action taken with <Semaphore x="1131427" class="Medicine" value="Revlimid" score="0.74" ID="256603">Revlimid </Semaphore>for the <Semaphore x="2056128" class="Disease or Finding" value="Influenza" score="1.00" ID="C53482">flu </Semaphore>was not provided. The action taken for <Semaphore x="2910051" class="MedDRA LLT" value="Disease progression" score="1.00" ID="10061818">disease <Semaphore x="3115684" class="MedDRA LLT" value="Multiple myeloma" score="1.00" ID="10028228">progression </Semaphore></Semaphore>
    <Semaphore x="3115684" class="MedDRA LLT" value="Multiple myeloma" score="1.00" ID="10028228">(multiple myeloma</Semaphore>) was <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">therapy </Semaphore>was permanently discontinued on 14Jan2013.The patient will go into <Semaphore x="2032278" class="Procedure" value="Hospice Care" score="1.00" ID="C15252">hospice care </Semaphore>once <Semaphore x="1854022" class="Disease or Finding" value="Discoid Lupus Erythematosus" score="1.00" ID="C26820">released </Semaphore>from the hospital.The reporter deemed the event of <Semaphore x="2910051" class="MedDRA LLT" value="Disease progression" score="1.00" ID="10061818">disease <Semaphore x="3115684" class="MedDRA LLT" value="Multiple myeloma" score="1.00" ID="10028228">progression </Semaphore></Semaphore>
    <Semaphore x="3115684" class="MedDRA LLT" value="Multiple myeloma" score="1.00" ID="10028228">(multiple myeloma</Semaphore>) as life threatening.The <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200"><Semaphore x="1854548" class="Disease or Finding" value="Disease Outcome" score="1.00" ID="C18226">outcome of <Semaphore x="2910051" class="MedDRA LLT" value="Disease progression" score="1.00" ID="10061818">disease </Semaphore></Semaphore>
     </Semaphore>
    <Semaphore x="3115684" class="MedDRA LLT" value="Multiple myeloma" score="1.00" ID="10028228">progression </Semaphore>
    <Semaphore x="3115684" class="MedDRA LLT" value="Multiple myeloma" score="1.00" ID="10028228">(multiple myeloma</Semaphore>) was not recovered. The <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome </Semaphore>of <Semaphore x="2056128" class="Disease or Finding" value="Influenza" score="1.00" ID="C53482">flu </Semaphore>was unknown.The reporter assessed the causal <Semaphore x="1854566" class="Disease or Finding" value="Disease Response" score="1.00" ID="C50995">relationship for <Semaphore x="2910051" class="MedDRA LLT" value="Disease progression" score="1.00" ID="10061818">disease </Semaphore></Semaphore>
    <Semaphore x="3115684" class="MedDRA LLT" value="Multiple myeloma" score="1.00" ID="10028228">progression </Semaphore>
    <Semaphore x="3115684" class="MedDRA LLT" value="Multiple myeloma" score="1.00" ID="10028228">(multiple myeloma</Semaphore>) as related to <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">therapy</Semaphore>. The reporter did not provide a causality <Semaphore x="2397639" class="Procedure" value="Physical Examination" score="1.00" ID="C20989">assessment </Semaphore>for the event of <Semaphore x="2056128" class="Disease or Finding" value="Influenza" score="1.00" ID="C53482">flu </Semaphore>and <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">therapy</Semaphore>.Additional information will be requested from the prescriber.</narrativeincludeclinical>
        <sendercomment lang="en">A causal relationship between therapy and DISEASE PROGRESSION (MULTIPLE MYELOMA) is considered not related due to confounding by underlying disease.</sendercomment>
      </summary>
    </patient>
  </safetyreport>
</ichicsr></original></faers>